🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Low Dose Naltrexone 4.5 mg

$105.00$1.75 per tablet · 60 tablets
Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in discreet packaging with a tracking number. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email order@pharmeasybank.com.

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

What Is Low Dose Naltrexone 4.5 mg?

Low Dose Naltrexone 4.5 mg, commonly called LDN, is a low-dose formulation of naltrexone, a prescription medicine that acts primarily as an opioid receptor antagonist.

Naltrexone is traditionally prescribed at substantially higher doses for alcohol use disorder and opioid use disorder.

Low-dose naltrexone generally refers to doses substantially below those used for these approved indications, often approximately 1–5 mg daily in clinical practice and research.

Researchers have proposed that low-dose naltrexone may influence pain processing, immune signaling and neuroinflammatory pathways.

However, these mechanisms have not been fully established in humans, and clinical research remains preliminary or mixed.

LDN is sometimes prescribed off-label by healthcare professionals for selected patients who have not responded adequately to conventional treatment.

Important: Low-dose naltrexone is not a proven cure for autoimmune diseases, chronic fatigue syndrome, fibromyalgia, multiple sclerosis or other chronic conditions.

How Does Low Dose Naltrexone 4.5 mg Work?

1. Opioid Receptor Antagonism

Naltrexone binds to opioid receptors and blocks the effects of opioid agonists.

This is its established pharmacological action.

2. Possible Effects on Pain Signaling

Researchers are investigating whether low doses of naltrexone may influence pathways involved in chronic pain perception.

The clinical significance of these effects remains uncertain.

3. Proposed Neuroimmune Modulation

Some laboratory research suggests that naltrexone may influence neuroimmune signaling.

These effects have not been conclusively demonstrated as a clinical treatment mechanism in humans.

4. Proposed Microglial Effects

Low-dose naltrexone has been studied for possible effects on microglial activity.

Microglia are immune-related cells in the central nervous system.

However, the hypothesis that LDN improves human disease by reducing microglial activation remains unproven.

5. Possible Influence on Inflammatory Signaling

Researchers have investigated whether LDN may alter certain inflammatory pathways.

Clinical evidence is insufficient to establish it as a general anti-inflammatory treatment.

6. Possible Effects on Endogenous Opioid Systems

A proposed theory suggests that temporary opioid receptor blockade may influence endogenous opioid signaling.

This remains a hypothesis rather than a confirmed explanation for clinical benefits.

7. Potential Symptom Modulation

Small studies and clinical observations have explored possible improvements in pain and other symptoms.

Results vary, and larger, well-designed clinical trials are needed.

Potential Uses of Low Dose Naltrexone 4.5 mg

The following are investigational or off-label applications. They should not be described as established or FDA-approved indications for LDN.

1. Fibromyalgia

Low-dose naltrexone has been investigated for fibromyalgia, a condition associated with widespread pain, fatigue and sleep disturbances.

Some small studies have reported potential benefits, while other controlled studies have not demonstrated a clear advantage over placebo.

The overall evidence remains insufficient for routine recommendation.

2. Chronic Pain Conditions

LDN has been explored as a possible treatment for selected chronic pain conditions.

Research is ongoing, and effectiveness has not been established across chronic pain disorders.

3. Multiple Sclerosis

Low-dose naltrexone has been studied for symptoms and quality-of-life outcomes in people with multiple sclerosis.

Available evidence does not establish that LDN prevents relapses, reduces disease activity or slows disability progression.

It is not a substitute for approved disease-modifying treatments.

4. Crohn’s Disease

Small studies have investigated LDN in Crohn’s disease.

The evidence remains limited, and LDN is not an established treatment for inducing or maintaining remission.

5. Chronic Fatigue Syndrome / ME/CFS

LDN is sometimes prescribed off-label for myalgic encephalomyelitis/chronic fatigue syndrome.

However, robust clinical trial evidence demonstrating effectiveness is lacking.

6. Neuropathic Pain

Researchers have explored low-dose naltrexone for selected neuropathic pain conditions.

Evidence remains preliminary.

7. Complex Regional Pain Syndrome

LDN has been discussed as an experimental approach for complex regional pain syndrome.

Clinical evidence is limited and does not establish effectiveness.

8. Other Inflammatory or Autoimmune Conditions

Low-dose naltrexone is sometimes discussed in relation to autoimmune and inflammatory disorders.

However, its effectiveness and safety for these indications have not been established through sufficiently rigorous clinical trials.

Important: LDN should not replace established treatment for autoimmune disease, inflammatory bowel disease, multiple sclerosis or other serious medical conditions.

How to Take Low Dose Naltrexone 4.5 mg

Low Dose Naltrexone should be taken only according to a healthcare professional’s prescription.

General Administration Instructions

  1. Confirm the prescribed strength and formulation.
  2. Verify that the medicine is naltrexone and not another similarly named product.
  3. Take the prescribed dose according to the clinician’s instructions.
  4. Follow the dispensing pharmacy’s administration instructions.
  5. Do not increase the dose without medical advice.
  6. Inform the prescriber about all current medicines.
  7. Avoid combining naltrexone with opioid medicines unless specifically managed by a qualified specialist.
  8. Report persistent adverse effects.
  9. Attend scheduled medical follow-up appointments.
  10. Do not discontinue other prescribed treatments without medical guidance.

Dosage Information

Low-dose naltrexone is commonly studied or prescribed off-label at doses ranging from approximately 1 mg to 5 mg daily.

4.5 mg once daily is a commonly studied dose, but it is not an FDA-established dosing recommendation for chronic pain or inflammatory conditions.

Some clinicians begin with lower doses and adjust treatment according to individual response and tolerability.

There is no universally accepted LDN dosing protocol for its investigated off-label indications.

When Should LDN Be Taken?

LDN is sometimes prescribed in the evening.

However, some patients who experience sleep disturbances may be advised to take it at another time.

There is no universally established optimal administration time.

Can LDN Be Taken With Food?

Naltrexone may generally be taken with or without food.

Follow the specific compounded product’s instructions.

What If a Dose Is Missed?

Follow the prescriber’s instructions.

Do not double the next dose to compensate.

Can LDN Be Stopped Suddenly?

Naltrexone is not generally associated with the same physical dependence or withdrawal syndrome as opioid agonists.

However, patients should discuss discontinuation with their prescriber, especially when LDN is being used as part of a broader treatment plan.

How Long Does Low Dose Naltrexone Take to Work?

There is no established or reliably predictable onset of benefit for LDN’s off-label applications.

In some studies and clinical practice reports, symptom changes have been evaluated over several weeks.

First 1–2 Weeks

Some patients may notice adverse effects such as vivid dreams, sleep disturbances, headache or gastrointestinal symptoms.

Approximately 2–6 Weeks

Some individuals report changes in symptoms, although these reports do not establish treatment effectiveness.

Approximately 6–12 Weeks

Clinical studies often evaluate outcomes over several weeks or months.

Long-Term Use

The long-term effectiveness and safety of LDN for many off-label conditions have not been adequately established.

Important: Lack of improvement should prompt reassessment rather than automatic dose escalation.

Common Side Effects

Possible side effects include:

  • Vivid dreams
  • Sleep disturbances
  • Insomnia
  • Headache
  • Nausea
  • Abdominal discomfort
  • Dizziness
  • Fatigue
  • Anxiety
  • Irritability

The frequency of adverse effects specifically at 4.5 mg is not as well established as for standard-dose naltrexone.

Serious Side Effects

Seek urgent medical attention if any of the following occur:

  • Severe allergic reaction
  • Difficulty breathing
  • Severe abdominal pain
  • Yellowing of the skin or eyes
  • Dark urine with other signs of liver injury
  • Severe or persistent vomiting
  • Significant changes in mental health
  • Symptoms of precipitated opioid withdrawal

Important Serious Risks

Precipitated Opioid Withdrawal: Naltrexone can trigger withdrawal symptoms in individuals who are physically dependent on opioids.

Blocked Opioid Analgesia: Naltrexone may interfere with opioid pain medicines.

Liver Injury: Naltrexone has been associated with liver-related adverse effects, particularly at excessive doses or in susceptible patients.

Opioid Overdose Risk: Attempting to overcome opioid receptor blockade with large opioid doses can cause life-threatening overdose.

Reduced Opioid Tolerance: After discontinuing naltrexone, individuals may be more sensitive to opioids and face an increased overdose risk.

Contraindications & Precautions

1. Current Opioid Use

Patients using opioid analgesics or other opioid-containing medicines should not begin naltrexone without appropriate medical assessment.

2. Opioid Dependence

Naltrexone may precipitate acute withdrawal in opioid-dependent individuals.

3. Recent Opioid Exposure

An appropriate opioid-free interval may be necessary before initiating naltrexone.

The required interval depends on the opioid involved and individual circumstances.

4. Opioid Withdrawal

Naltrexone should not be started during acute opioid withdrawal.

5. Liver Disease

Patients with significant liver disease require careful assessment.

6. Acute Hepatitis

Naltrexone should not be used in patients with acute hepatitis or liver failure under standard prescribing precautions.

7. Kidney Disease

Patients with kidney impairment may require additional monitoring.

8. Pregnancy

The safety of LDN for off-label conditions during pregnancy has not been adequately established.

9. Breastfeeding

Naltrexone passes into breast milk in small amounts.

Treatment decisions require individualized medical assessment.

10. Children

The safety and effectiveness of LDN 4.5 mg for pediatric off-label conditions have not been established.

11. Older Adults

Older adults may require individualized assessment because of other medical conditions and concurrent medications.

12. Upcoming Surgery

Patients should inform their surgical and anesthesia teams if they are taking naltrexone.

The medicine may interfere with opioid-based pain management.

13. Chronic Pain Management

LDN should not replace established pain treatments without medical supervision.

14. Autoimmune Disorders

Patients should continue evidence-based disease management unless their specialist recommends changes.

15. Compounded Formulations

Low-dose naltrexone is commonly supplied as a compounded preparation.

Compounded medicines are not FDA-approved as finished products, and quality depends on appropriate pharmacy standards.

16. Medication Interactions

Important potential interactions or treatment conflicts include:

  • Morphine
  • Oxycodone
  • Hydrocodone
  • Codeine
  • Tramadol
  • Fentanyl
  • Methadone
  • Buprenorphine
  • Other opioid-containing medicines
  • Certain cough and diarrhea medicines containing opioids

Patients should inform their prescriber about every prescription medicine, over-the-counter product and supplement they use.

17. Mental Health Monitoring

Patients should report new or worsening depression, anxiety or other significant psychological symptoms.

18. Medical Monitoring

Healthcare professionals may monitor:

  • Treatment response
  • Pain symptoms
  • Sleep patterns
  • Adverse effects
  • Liver function when clinically indicated
  • Current opioid exposure
  • Medication interactions
  • Underlying disease activity
  • Quality-of-life outcomes
  • Continued need for off-label treatment

Potential Advantages

  • Oral administration.
  • Low-dose formulation.
  • Commonly studied at 4.5 mg.
  • Established opioid receptor antagonist mechanism.
  • Investigated for fibromyalgia.
  • Investigated for selected chronic pain conditions.
  • Investigated for certain inflammatory disorders.
  • Potentially useful in carefully selected off-label treatment plans.
  • May be prescribed in individualized compounded strengths.
  • Generally not associated with opioid-like physical dependence.

Note: These characteristics do not establish clinical effectiveness for unapproved conditions.

Disadvantages / Limitations

  • Not FDA-approved for chronic pain.
  • Not FDA-approved for fibromyalgia.
  • Not FDA-approved for autoimmune disorders.
  • Limited high-quality clinical evidence.
  • Mixed findings in controlled studies.
  • No universally accepted off-label dosing protocol.
  • May cause vivid dreams.
  • May cause insomnia.
  • May cause headaches.
  • May cause nausea.
  • May cause dizziness.
  • May interfere with opioid pain medicines.
  • Can precipitate opioid withdrawal.
  • Requires caution in liver disease.
  • Long-term safety for off-label indications remains incompletely characterized.
  • Often requires compounding.
  • Compounded products are not FDA-approved finished medicines.
  • Does not replace established disease-specific treatments.

Important Notes

Generic Name: Naltrexone.

Common Form: Naltrexone Hydrochloride.

Strength: 4.5 mg.

Common Abbreviation: LDN.

Dosage Form: Commonly Compounded Oral Capsules.

Drug Class: Opioid Receptor Antagonist.

Therapeutic Category: Prescription Medicine / Off-Label Therapy.

Established Mechanism: Opioid receptor antagonism.

Investigational Mechanisms: Possible effects on neuroimmune and inflammatory signaling.

Potential Off-Label Applications: Fibromyalgia, selected chronic pain conditions and certain inflammatory disorders.

FDA Approval: Naltrexone is approved for specific substance use disorders at standard doses; 4.5 mg LDN is not FDA-approved for chronic pain or autoimmune conditions.

Dosage: Individualized by the prescriber.

Opioid Warning: May precipitate withdrawal or interfere with opioid pain relief.

Liver Precaution: Requires assessment in patients with liver disease.

Pregnancy Precaution: Requires individualized medical assessment.

Storage: Follow the dispensing pharmacy’s instructions.

Frequently Asked Questions

1. What is Low Dose Naltrexone 4.5 mg used for?

LDN 4.5 mg is prescribed off-label by some healthcare professionals for selected conditions such as fibromyalgia and chronic pain. Its effectiveness for these conditions is not firmly established.

2. What is the active ingredient in LDN 4.5 mg?

The active ingredient is naltrexone, commonly supplied as naltrexone hydrochloride.

3. Is Low Dose Naltrexone an opioid?

No. Naltrexone is an opioid receptor antagonist, not an opioid painkiller.

4. How does Low Dose Naltrexone work?

Its established action is opioid receptor blockade. Other proposed effects on pain and immune signaling remain under investigation.

5. Can LDN help with fibromyalgia?

Some small studies have suggested potential benefits, but controlled evidence is mixed and insufficient to establish LDN as a standard fibromyalgia treatment.

6. Can LDN treat chronic pain?

LDN is being investigated for selected chronic pain conditions, but effectiveness has not been established across these disorders.

7. Can LDN treat autoimmune diseases?

There is insufficient evidence to establish LDN as an effective treatment for autoimmune diseases.

8. Can LDN treat multiple sclerosis?

LDN has been studied in multiple sclerosis, but it has not been shown to replace disease-modifying treatments or prevent disease progression.

Product DetailsInformation
Product NameLow Dose Naltrexone 4.5 mg
Common AbbreviationLDN 4.5 mg
Generic NameNaltrexone
Active IngredientNaltrexone, commonly as Naltrexone Hydrochloride
Strength4.5 mg
Dosage FormCommonly Compounded Oral Capsules
Route of AdministrationOral
Drug ClassOpioid Receptor Antagonist
Therapeutic CategoryPrescription Medicines / Investigational and Off-Label Therapies
Potential Off-Label ApplicationsFibromyalgia, selected chronic pain conditions and certain inflammatory disorders
FDA-Approved Uses of Naltrexone at Standard DosesAlcohol Use Disorder and Opioid Use Disorder
FDA Approval for Low-Dose ApplicationsNot FDA-approved
ManufacturerDepends on the dispensing or compounding pharmacy
Pack SizeVaries by supplier
Prescription StatusPrescription Medicine
StorageFollow the dispensing pharmacy's instructions
Pack sizes60 tablets, 120 tablets, 180 tablets, 240 tablets, 300 tablets
Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.